Physician profile
Peter E Lantz
NPI 1659358570
$22,699.01
in general payments reported to CMS, 2019-2025
65 companies · $2,723 in 2025
The $2,723 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,421 · 2020: $2,140 · 2021: $3,560 · 2022: $3,782 · 2023: $2,959 · 2024: $2,115 · 2025: $2,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,796.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,534.20 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $2,112.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,834.84 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Amgen INC. | $1,444.54 | 2019-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $1,383.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,167.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $1,166.88 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Pfizer INC. | $1,024.34 | 2019-2025 | |
| Lilly USA, LLC | $837.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $766.02 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $650.21 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $645.37 | 2022-2025 | Rexulti, Nuedexta |
| Amarin Pharma, INC. | $592.97 | 2019-2022 | |
| Abbott Laboratories | $533.97 | 2019-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $511.98 | 2019-2025 | Veozah, Myrbetriq |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.